stockrow
Friday 6 November 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- Revenue
- +12.5%
- EPS
- +84.6%
- Free cash flow
- +237.7%
- Total debt
- −5.97%
Quarter to September 2026, against a year earlier
2.15
0.28
−11.52%
Follow STIM
Alert me
Neuronetics, Inc. (STIM) P/E ratio
Neuronetics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RXST RxSight, Inc. compare | n/m |
| INGN Inogen, Inc compare | n/m |
| STIM Neuronetics, Inc. | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| PROF Profound Medical compare | n/m |
| LAB Standard BioTools Inc. compare | 1.8× |
| ELMD Electromed, Inc. compare | 19.4× |
| INFU InfuSystems Holdings, Inc. compare | 32.0× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)